KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Other Accumulated Expenses (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Other Accumulated Expenses for 16 consecutive years, with $3.4 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other Accumulated Expenses rose 19.14% year-over-year to $3.4 billion, compared with a TTM value of $3.4 billion through Sep 2024, up 19.14%, and an annual FY2023 reading of $3.2 billion, down 3.22% over the prior year.
  • Other Accumulated Expenses was $3.4 billion for Q3 2024 at Thermo Fisher Scientific, up from $3.0 billion in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.4 billion in Q3 2024 and bottomed at $1.5 billion in Q1 2020.
  • Average Other Accumulated Expenses over 5 years is $2.7 billion, with a median of $3.0 billion recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses surged 58.89% in 2022, then decreased 11.17% in 2023.
  • Year by year, Other Accumulated Expenses stood at $2.3 billion in 2020, then increased by 27.48% to $3.0 billion in 2021, then rose by 13.69% to $3.4 billion in 2022, then decreased by 3.22% to $3.2 billion in 2023, then grew by 4.53% to $3.4 billion in 2024.
  • Business Quant data shows Other Accumulated Expenses for TMO at $3.4 billion in Q3 2024, $3.0 billion in Q2 2024, and $3.0 billion in Q1 2024.